The slide above illustrates the role of PPARα, PPARβ/δ and PPARγ as key regulators of lipid metabolism, inflammation and glucose metabolism. Understanding the role of various peroxisome proliferator-activated receptors and their ligands in clinical practice is very important for the future of NASH management. It illustrates why a “pan” PPAR approach can be beneficial and why more research is needed.
Do you want to learn more about definitions and epidemiology? Download the first 75 slides of the PanNASH slide kit below.
- Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018; 3(7): 509-17.
- 1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13(4): 643-54.e1-9; quiz e39-40.